Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355658 | 0.89 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL14015908 | 0.84 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL12155334 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2PKMMEN1KMT2ACYP1A2 | |
| SCHEMBL2240998 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2PKMMEN1KMT2ACYP1A2 | |
| SCHEMBL20563868 | 0.82 | POLB (0.62) | SMN1; SMN2PKMMEN1KMT2ACYP1A2 | |
| SCHEMBL2241005 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2PKMMEN1KMT2ACYP1A2 | |
| SCHEMBL14355655 | 0.81 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL13301273 | 0.81 | POLB (0.58) | LMNASMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL23464918 | 0.80 | — | — | |
| SCHEMBL1564357 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2PKMMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-7300948-B2 | Alkynyl compounds as non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | LMNA 612/4885SMN1; SMN2 1109/4885PKM 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.